Peptide Library

Human study PLS-00185

Thymosin beta(4) and beta(10) levels in pre-term newborn oral cavity and foetal salivary glands evidence a switch of secretion during foetal development.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Thymosin beta(4) and beta(10) levels in pre-term newborn oral cavity and foetal salivary glands evidence a switch of secretion during foetal development.primary · PloS one · 2009-04-01 · PMID 19337364 · DOI

Design and participants

Design
Cross-sectional study
Population
Human pre-term newborns (whole saliva) and pre-term fetuses (salivary gland tissue), with infant and adult comparison material
Conditions
Prematurity, Fetal salivary gland development
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Non-U.S. government research support (per PubMed publication type); funder not named

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Fetal salivary glands express and secrete beta-thymosins, probably involved in oral cavity development. Secretion rises from about 12 to 21 weeks of gestation and then falls near term, when the glands switch to adult-type salivary peptides.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Endogenous peptide levels were measured; no thymosin beta-4 was administered, so the study gives no information on treatment effects or safety.
    • abstract only: Only the abstract is available in the record; sample sizes and methods are not reported.
    • no control group: Observational measurement of endogenous peptide levels with no intervention and no comparison group of treated participants.
    • inappropriate population: Pre-term newborns and fetal tissue, with no administration of thymosin beta-4, so the study is unlike any clinical treatment question.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 19337364, abstract (Significance, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 19337364, abstract (Background, sentence 1 and Methodology/principal findings) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 19337364, title (PubMed publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 19337364, abstract (Background, sentence 1; Methodology, sentence 3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).